{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:17:21Z","timestamp":1790705841329,"version":"4.1.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2014,10,28]],"date-time":"2014-10-28T00:00:00Z","timestamp":1414454400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s00213-014-3780-2","type":"journal-article","created":{"date-parts":[[2014,10,27]],"date-time":"2014-10-27T03:15:18Z","timestamp":1414379718000},"page":"1427-1440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["A systematic microdialysis study of dopamine transmission in the accumbens shell\/core and prefrontal cortex after acute antipsychotics"],"prefix":"10.1007","volume":"232","author":[{"given":"Gianluigi","family":"Tanda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Valentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Perra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Pietro","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Di Chiara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,28]]},"reference":[{"key":"3780_CR1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.eurpsy.2004.11.003","volume":"20","author":"A Abi-Dargham","year":"2005","unstructured":"Abi-Dargham A, Laruelle M (2005) Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatr J Assoc Eur Psychiatrists 20:15\u201327","journal-title":"Eur Psychiatr J Assoc Eur Psychiatrists"},{"key":"3780_CR2","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1523\/JNEUROSCI.22-09-03708.2002","volume":"22","author":"A Abi-Dargham","year":"2002","unstructured":"Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, Hwang DR, Keilp J, Kochan L, Van Heertum R, Gorman JM, Laruelle M (2002) Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci Off J Soc Neurosci 22:3708\u20133719","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"3780_CR3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0197-0186(02)00227-9","volume":"43","author":"YU Adachi","year":"2003","unstructured":"Adachi YU, Aramaki Y, Satomoto M, Higuchi H, Watanabe K (2003) Halothane attenuated haloperidol and enhanced clozapine-induced dopamine release in the rat striatum. Neurochem Int 43:113\u2013119","journal-title":"Neurochem Int"},{"key":"3780_CR4","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.neuint.2007.07.012","volume":"52","author":"YU Adachi","year":"2008","unstructured":"Adachi YU, Yamada S, Satomoto M, Higuchi H, Watanabe K, Kazama T, Mimuro S, Sato S (2008) Isoflurane anesthesia inhibits clozapine- and risperidone-induced dopamine release and anesthesia-induced changes in dopamine metabolism was modified by fluoxetine in the rat striatum: an in vivo microdialysis study. Neurochem Int 52:384\u2013391","journal-title":"Neurochem Int"},{"key":"3780_CR5","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.2042-7158.1973.tb10025.x","volume":"25","author":"NE Anden","year":"1973","unstructured":"Anden NE, Stock G (1973) Effect of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system. J Pharm Pharmacol 25:346\u2013348","journal-title":"J Pharm Pharmacol"},{"key":"3780_CR6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0014-2999(70)90006-3","volume":"11","author":"NE Anden","year":"1970","unstructured":"Anden NE, Butcher SG, Corrodi H, Fuxe K, Ungerstedt U (1970) Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Eur J Pharmacol 11:303\u2013314","journal-title":"Eur J Pharmacol"},{"key":"3780_CR7","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/BF00172774","volume":"352","author":"JL Andersson","year":"1995","unstructured":"Andersson JL, Nomikos GG, Marcus M, Hertel P, Mathe JM, Svensson TH (1995) Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system. Naunyn Schmiedeberg\u2019s Arch Pharmacol 352:374\u2013385","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"3780_CR8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0893-133X(97)00112-7","volume":"18","author":"J Arnt","year":"1998","unstructured":"Arnt J, Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 18:63\u2013101","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"key":"3780_CR9","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF02246025","volume":"104","author":"R Axelsson","year":"1991","unstructured":"Axelsson R, Nilsson A, Christensson E, Bjork A (1991) Effects of amperozide in schizophrenia. An open study of a potent 5-HT2 receptor antagonist. Psychopharmacology 104:287\u2013292","journal-title":"Psychopharmacology"},{"key":"3780_CR10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/00003088-198713020-00001","volume":"13","author":"AE Balant-Gorgia","year":"1987","unstructured":"Balant-Gorgia AE, Balant L (1987) Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring. Clin Pharmacokinet 13:65\u201390","journal-title":"Clin Pharmacokinet"},{"key":"3780_CR11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.2042-7158.1976.tb04648.x","volume":"28","author":"G Bartholini","year":"1976","unstructured":"Bartholini G (1976) Differential effect of neuroleptic drugs on dopamine turnover in the extrapyramidal and limbic system. J Pharm Pharmacol 28:429\u2013433","journal-title":"J Pharm Pharmacol"},{"key":"3780_CR12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0920-9964(94)00043-8","volume":"14","author":"A Breier","year":"1995","unstructured":"Breier A (1995) Serotonin, schizophrenia and antipsychotic drug action. Schizophr Res 14:187\u2013202","journal-title":"Schizophr Res"},{"key":"3780_CR13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1749-6632.1988.tb42097.x","volume":"537","author":"BS Bunney","year":"1988","unstructured":"Bunney BS (1988) Effects of acute and chronic neuroleptic treatment on the activity of midbrain dopamine neurons. Ann N Y Acad Sci 537:77\u201385","journal-title":"Ann N Y Acad Sci"},{"key":"3780_CR14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00004714-199604000-00010","volume":"16","author":"MJ Byerly","year":"1996","unstructured":"Byerly MJ, DeVane CL (1996) Pharmacokinetics of clozapine and risperidone: a review of recent literature. J Clin Psychopharmacol 16:177\u2013187","journal-title":"J Clin Psychopharmacol"},{"key":"3780_CR15","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.pnpbp.2003.09.008","volume":"27","author":"FP Bymaster","year":"2003","unstructured":"Bymaster FP, Felder CC, Tzavara E, Nomikos GG, Calligaro DO, McKinzie DL (2003) Muscarinic mechanisms of antipsychotic atypicality. Prog Neuro-Psychopharmacol Biol Psychiatry 27:1125\u20131143","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"3780_CR16","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.neuint.2012.07.008","volume":"61","author":"ES Calipari","year":"2012","unstructured":"Calipari ES, Huggins KN, Mathews TA, Jones SR (2012) Conserved dorsal-ventral gradient of dopamine release and uptake rate in mice, rats and rhesus macaques. Neurochem Int 61:986\u2013991","journal-title":"Neurochem Int"},{"key":"3780_CR17","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0893-133X(99)00085-8","volume":"22","author":"E Carboni","year":"2000","unstructured":"Carboni E, Rolando MT, Silvagni A, Di Chiara G (2000) Increase of dialysate dopamine in the bed nucleus of stria terminalis by clozapine and related neuroleptics. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 22:140\u2013147","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"key":"3780_CR18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0022-3956(74)90070-3","volume":"11","author":"A Carlsson","year":"1974","unstructured":"Carlsson A (1974) Antipsychotic drugs and catecholamine synapses. J Psychiatr Res 11:57\u201364","journal-title":"J Psychiatr Res"},{"key":"3780_CR19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1600-0773.1963.tb01730.x","volume":"20","author":"A Carlsson","year":"1963","unstructured":"Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20:140\u2013144","journal-title":"Acta Pharmacol Toxicol"},{"key":"3780_CR20","first-page":"189","volume":"17","author":"GB Cassano","year":"1975","unstructured":"Cassano GB, Castrogiovanni P, Conti L, Bonollo L (1975) Sulpiride versus haloperidol in schizophrenia: a double-blind comparative trial. Curr Ther Res Clin Exp 17:189\u2013201","journal-title":"Curr Ther Res Clin Exp"},{"key":"3780_CR21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.schres.2006.07.011","volume":"88","author":"ML Chew","year":"2006","unstructured":"Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Kirshner MA, Bies RR, Kapur S, Gharabawi G (2006) A model of anticholinergic activity of atypical antipsychotic medications. Schizophr Res 88:63\u201372","journal-title":"Schizophr Res"},{"key":"3780_CR22","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1523\/JNEUROSCI.03-08-01607.1983","volume":"3","author":"LA Chiodo","year":"1983","unstructured":"Chiodo LA, Bunney BS (1983) Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci Off J Soc Neurosci 3:1607\u20131619","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"3780_CR23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF02245331","volume":"116","author":"JG Csernansky","year":"1994","unstructured":"Csernansky JG, Newcomer JW, Jackson K, Lombrozo L, Faull KF, Zipursky R, Pfefferbaum A, Faustman WO (1994) Effects of raclopride treatment on plasma and CSF HVA: relationships with clinical improvement in male schizophrenics. Psychopharmacology 116:291\u2013296","journal-title":"Psychopharmacology"},{"key":"3780_CR24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0306-4522(92)90007-O","volume":"46","author":"AY Deutch","year":"1992","unstructured":"Deutch AY, Cameron DS (1992) Pharmacological characterization of dopamine systems in the nucleus accumbens core and shell. Neuroscience 46:49\u201356","journal-title":"Neuroscience"},{"key":"3780_CR25","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/1044-7431(92)90030-6","volume":"3","author":"AY Deutch","year":"1992","unstructured":"Deutch AY, Lee MC, Iadarola MJ (1992) Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Mol Cell Neurosci 3:332\u2013341","journal-title":"Mol Cell Neurosci"},{"key":"3780_CR26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0166-4328(02)00286-3","volume":"137","author":"G Chiara Di","year":"2002","unstructured":"Di Chiara G (2002) Nucleus accumbens shell and core dopamine: differential role in behavior and addiction. Behav Brain Res 137:75\u2013114","journal-title":"Behav Brain Res"},{"key":"3780_CR27","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/syn.890130308","volume":"13","author":"RP Dilts Jr","year":"1993","unstructured":"Dilts RP Jr, Helton TE, McGinty JF (1993) Selective induction of Fos and FRA immunoreactivity within the mesolimbic and mesostriatal dopamine terminal fields. Synapse 13:251\u2013263","journal-title":"Synapse"},{"key":"3780_CR28","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0306-4522(90)90399-O","volume":"37","author":"M Dragunow","year":"1990","unstructured":"Dragunow M, Robertson GS, Faull RL, Robertson HA, Jansen K (1990) D2 dopamine receptor antagonists induce Fos and related proteins in rat striatal neurons. Neuroscience 37:287\u2013294","journal-title":"Neuroscience"},{"key":"3780_CR29","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00213-007-0973-y","volume":"196","author":"O Franberg","year":"2008","unstructured":"Franberg O, Wiker C, Marcus MM, Konradsson A, Jardemark K, Schilstrom B, Shahid M, Wong EH, Svensson TH (2008) Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology 196:417\u2013429","journal-title":"Psychopharmacology"},{"key":"3780_CR30","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","volume":"167","author":"DM Gardner","year":"2010","unstructured":"Gardner DM, Murphy AL, O\u2019Donnell H, Centorrino F, Baldessarini RJ (2010) International consensus study of antipsychotic dosing. Am J Psychiatry 167:686\u2013693","journal-title":"Am J Psychiatry"},{"key":"3780_CR31","doi-asserted-by":"crossref","unstructured":"Ginovart N, Kapur S (2012) Role of dopamine D(2) receptors for antipsychotic activity. Handb Exp Pharmacol 27\u201352","DOI":"10.1007\/978-3-642-25761-2_2"},{"key":"3780_CR32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0166-2236(96)10064-3","volume":"20","author":"AA Grace","year":"1997","unstructured":"Grace AA, Bunney BS, Moore H, Todd CL (1997) Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci 20:31\u201337","journal-title":"Trends Neurosci"},{"key":"3780_CR33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-0447.1984.tb06856.x","volume":"311","author":"C Harnryd","year":"1984","unstructured":"Harnryd C, Bjerkenstedt L, Bjork K, Gullberg B, Oxenstierna G, Sedvall G, Wiesel FA, Wik G, Aberg-Wistedt A (1984) Clinical evaluation of sulpiride in schizophrenic patients\u2014a double-blind comparison with chlorpromazine. Acta Psychiatr Scand Suppl 311:7\u201330","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"3780_CR34","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/sj.npp.1300244","volume":"28","author":"S Hartter","year":"2003","unstructured":"Hartter S, Huwel S, Lohmann T, Abou El Ela A, Langguth P, Hiemke C, Galla HJ (2003) How does the benzamide antipsychotic amisulpride get into the brain?\u2014An in vitro approach comparing amisulpride with clozapine. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 28:1916\u20131922","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"key":"3780_CR35","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1176\/jnp.9.3.354","volume":"9","author":"L Heimer","year":"1997","unstructured":"Heimer L, Alheid GF, de Olmos JS, Groenewegen HJ, Haber SN, Harlan RE, Zahm DS (1997) The accumbens: beyond the core-shell dichotomy. J Neuropsychiatry Clin Neurosci 9:354\u2013381","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"3780_CR36","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/BF02245607","volume":"124","author":"P Hertel","year":"1996","unstructured":"Hertel P, Nomikos GG, Iurlo M, Svensson TH (1996) Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology 124:74\u201386","journal-title":"Psychopharmacology"},{"key":"3780_CR37","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1111\/j.1471-4159.1992.tb10975.x","volume":"58","author":"J Ichikawa","year":"1992","unstructured":"Ichikawa J, Meltzer HY (1992) Amperozide, a novel antipsychotic drug, inhibits the ability of d-amphetamine to increase dopamine release in vivo in rat striatum and nucleus accumbens. J Neurochem 58:2285\u20132291","journal-title":"J Neurochem"},{"key":"3780_CR38","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0006-8993(99)02346-X","volume":"858","author":"J Ichikawa","year":"2000","unstructured":"Ichikawa J, Meltzer HY (2000) The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. Brain Res 858:252\u2013263","journal-title":"Brain Res"},{"key":"3780_CR39","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0014-2999(98)00308-2","volume":"351","author":"J Ichikawa","year":"1998","unstructured":"Ichikawa J, Kuroki T, Dai J, Meltzer HY (1998) Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur J Pharmacol 351:163\u2013171","journal-title":"Eur J Pharmacol"},{"key":"3780_CR40","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1046\/j.1471-4159.2001.00154.x","volume":"76","author":"J Ichikawa","year":"2001","unstructured":"Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O\u2019Laughlin IA, Meltzer HY (2001) 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76:1521\u20131531","journal-title":"J Neurochem"},{"key":"3780_CR41","first-page":"383","volume":"25","author":"A Imperato","year":"1989","unstructured":"Imperato A, Angelucci L (1989) The effects of clozapine and fluperlapine on the in vivo release and metabolism of dopamine in the striatum and in the prefrontal cortex of freely moving rats. Psychopharmacol Bull 25:383\u2013389","journal-title":"Psychopharmacol Bull"},{"key":"3780_CR42","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1523\/JNEUROSCI.05-02-00297.1985","volume":"5","author":"A Imperato","year":"1985","unstructured":"Imperato A, Di Chiara G (1985) Dopamine release and metabolism in awake rats after systemic neuroleptics as studied by trans-striatal dialysis. J Neurosci Off J Soc Neurosci 5:297\u2013306","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"3780_CR43","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2165\/00003088-199324020-00005","volume":"24","author":"MW Jann","year":"1993","unstructured":"Jann MW, Grimsley SR, Gray EC, Chang WH (1993) Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 24:161\u2013176","journal-title":"Clin Pharmacokinet"},{"key":"3780_CR44","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/j.1552-4604.1994.tb01995.x","volume":"34","author":"JI Javaid","year":"1994","unstructured":"Javaid JI (1994) Clinical pharmacokinetics of antipsychotics. J Clin Pharmacol 34:286\u2013295","journal-title":"J Clin Pharmacol"},{"key":"3780_CR45","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1007\/s11095-011-0477-7","volume":"28","author":"M Johnson","year":"2011","unstructured":"Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Li C, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH (2011) Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats. Pharm Res 28:2490\u20132504","journal-title":"Pharm Res"},{"key":"3780_CR46","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/(SICI)1098-2396(199607)23:3<224::AID-SYN12>3.0.CO;2-Z","volume":"23","author":"SR Jones","year":"1996","unstructured":"Jones SR, O\u2019Dell SJ, Marshall JF, Wightman RM (1996) Functional and anatomical evidence for different dopamine dynamics in the core and shell of the nucleus accumbens in slices of rat brain. Synapse 23:224\u2013231","journal-title":"Synapse"},{"key":"3780_CR47","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","volume":"158","author":"S Kapur","year":"2001","unstructured":"Kapur S, Seeman P (2001) Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 158:360\u2013369","journal-title":"Am J Psychiatry"},{"key":"3780_CR48","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/026988119701100205","volume":"11","author":"MB Knable","year":"1997","unstructured":"Knable MB, Weinberger DR (1997) Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol 11:123\u2013131","journal-title":"J Psychopharmacol"},{"key":"3780_CR49","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0022-3565(24)38019-X","volume":"288","author":"T Kuroki","year":"1999","unstructured":"Kuroki T, Meltzer HY, Ichikawa J (1999) Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288:774\u2013781","journal-title":"J Pharmacol Exp Ther"},{"key":"3780_CR50","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00213-005-0280-4","volume":"184","author":"D Lecca","year":"2006","unstructured":"Lecca D, Cacciapaglia F, Valentini V, Gronli J, Spiga S, Di Chiara G (2006) Preferential increase of extracellular dopamine in the rat nucleus accumbens shell as compared to that in the core during acquisition and maintenance of intravenous nicotine self-administration. Psychopharmacology 184:435\u2013446","journal-title":"Psychopharmacology"},{"key":"3780_CR51","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lassig B, Salanti G, Davis JM (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951\u2013962","journal-title":"Lancet"},{"key":"3780_CR52","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0006-8993(02)02620-3","volume":"947","author":"JF Liegeois","year":"2002","unstructured":"Liegeois JF, Ichikawa J, Meltzer HY (2002) 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res 947:157\u2013165","journal-title":"Brain Res"},{"key":"3780_CR53","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.euroneuro.2007.06.003","volume":"18","author":"K Linnet","year":"2008","unstructured":"Linnet K, Ejsing TB (2008) A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 18:157\u2013169","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol"},{"key":"3780_CR54","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0090-9556(25)08211-X","volume":"21","author":"G Mannens","year":"1993","unstructured":"Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J (1993) Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos Biol Fate Chem 21:1134\u20131141","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"3780_CR55","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0924-977X(95)00056-U","volume":"6","author":"MM Marcus","year":"1996","unstructured":"Marcus MM, Nomikos GG, Svensson TH (1996) Differential actions of typical and atypical antipsychotic drugs on dopamine release in the core and shell of the nucleus accumbens. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 6:29\u201338","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol"},{"key":"3780_CR56","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0924-977X(00)00077-8","volume":"10","author":"MM Marcus","year":"2000","unstructured":"Marcus MM, Nomikos GG, Svensson TH (2000) Effects of atypical antipsychotic drugs on dopamine output in the shell and core of the nucleus accumbens: role of 5-HT(2A) and alpha(1)-adrenoceptor antagonism. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 10:245\u2013253","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol"},{"key":"3780_CR57","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0924-977X(02)00048-2","volume":"12","author":"MM Marcus","year":"2002","unstructured":"Marcus MM, Malmerfelt A, Nyberg S, Svensson TH (2002) Biochemical effects in brain of low doses of haloperidol are qualitatively similar to those of high doses. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 12:379\u2013386","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol"},{"key":"3780_CR58","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2165\/00002018-199614050-00003","volume":"14","author":"MC Mauri","year":"1996","unstructured":"Mauri MC, Bravin S, Bitetto A, Rudelli R, Invernizzi G (1996) A risk-benefit assessment of sulpiride in the treatment of schizophrenia. Drug Saf Int J Med Toxicol Drug Experience 14:288\u2013298","journal-title":"Drug Saf Int J Med Toxicol Drug Experience"},{"key":"3780_CR59","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/schbul\/17.2.263","volume":"17","author":"HY Meltzer","year":"1991","unstructured":"Meltzer HY (1991) The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17:263\u2013287","journal-title":"Schizophr Bull"},{"key":"3780_CR60","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/j.1471-4159.1990.tb01230.x","volume":"54","author":"B Moghaddam","year":"1990","unstructured":"Moghaddam B, Bunney BS (1990) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 54:1755\u20131760","journal-title":"J Neurochem"},{"key":"3780_CR61","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11307-007-0124-1","volume":"10","author":"ED Morris","year":"2008","unstructured":"Morris ED, Normandin MD, Schiffer WK (2008) Initial comparison of ntPET with microdialysis measurements of methamphetamine-induced dopamine release in rats: support for estimation of dopamine curves from PET data. Mol Imaging Biol MIB Off Publ Acad Mol Imaging 10:67\u201373","journal-title":"Mol Imaging Biol MIB Off Publ Acad Mol Imaging"},{"key":"3780_CR62","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1124\/jpet.111.189076","volume":"341","author":"EC Muly","year":"2012","unstructured":"Muly EC, Votaw JR, Ritchie J, Howell LL (2012) Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone. J Pharmacol Exp Ther 341:81\u201389","journal-title":"J Pharmacol Exp Ther"},{"key":"3780_CR63","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/mp.2013.9","volume":"19","author":"R Narendran","year":"2014","unstructured":"Narendran R, Jedema HP, Lopresti BJ, Mason NS, Gurnsey K, Ruszkiewicz J, Chen CM, Deuitch L, Frankle WG, Bradberry CW (2014) Imaging dopamine transmission in the frontal cortex: a simultaneous microdialysis and [11C]FLB 457 PET study. Mol Psychiatry 19:302\u2013310","journal-title":"Mol Psychiatry"},{"key":"3780_CR64","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/BF02244765","volume":"115","author":"GG Nomikos","year":"1994","unstructured":"Nomikos GG, Iurlo M, Andersson JL, Kimura K, Svensson TH (1994) Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology 115:147\u2013156","journal-title":"Psychopharmacology"},{"key":"3780_CR65","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1755-5949.2010.00222.x","volume":"17","author":"M Nord","year":"2011","unstructured":"Nord M, Farde L (2011) Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther 17:97\u2013103","journal-title":"CNS Neurosci Ther"},{"key":"3780_CR66","volume-title":"The rat brain in stereotaxic coordinates","author":"G Paxinos","year":"1998","unstructured":"Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates, 4th edn. Academic, San Diego","edition":"4"},{"key":"3780_CR67","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0306-4522(92)90054-6","volume":"46","author":"GS Robertson","year":"1992","unstructured":"Robertson GS, Fibiger HC (1992) Neuroleptics increase c-Fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46:315\u2013328","journal-title":"Neuroscience"},{"key":"3780_CR68","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0022-3565(25)23800-9","volume":"271","author":"GS Robertson","year":"1994","unstructured":"Robertson GS, Matsumura H, Fibiger HC (1994) Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271:1058\u20131066","journal-title":"J Pharmacol Exp Ther"},{"key":"3780_CR69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hup.320","volume":"17","author":"P Rosenzweig","year":"2002","unstructured":"Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G (2002) A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol 17:1\u201313","journal-title":"Hum Psychopharmacol"},{"key":"3780_CR70","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ebmh1096","volume":"13","author":"C Rummel-Kluge","year":"2010","unstructured":"Rummel-Kluge C (2010) Negative symptoms are prevalent in antipsychotic-treated adult outpatients with schizophrenia spectrum disorders. Evid Based Ment Health 13:106","journal-title":"Evid Based Ment Health"},{"key":"3780_CR71","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(24)36395-5","volume":"280","author":"H Schoemaker","year":"1997","unstructured":"Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B (1997) Neurochemical characteristics of amisulpride, an atypical dopamine D2\/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280:83\u201397","journal-title":"J Pharmacol Exp Ther"},{"key":"3780_CR72","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/sj.npp.1300591","volume":"30","author":"CS Shilliam","year":"2005","unstructured":"Shilliam CS, Dawson LA (2005) The effect of clozapine on extracellular dopamine levels in the shell subregion of the rat nucleus accumbens is reversed following chronic administration: comparison with a selective 5-HT(2C) receptor antagonist. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 30:372\u2013380","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"issue":"Suppl 1","key":"3780_CR73","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-0773.1990.tb01599.x","volume":"66","author":"J Svartengren","year":"1990","unstructured":"Svartengren J, Simonsson P (1990) Receptor binding properties of amperozide. Pharmacol Toxicol 66(Suppl 1):8\u201311","journal-title":"Pharmacol Toxicol"},{"key":"3780_CR74","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1046\/j.1460-9568.1998.00135.x","volume":"10","author":"G Tanda","year":"1998","unstructured":"Tanda G, Di Chiara G (1998) A dopamine-mu1 opioid link in the rat ventral tegmentum shared by palatable food (Fonzies) and non-psychostimulant drugs of abuse. Eur J Neurosci 10:1179\u20131187","journal-title":"Eur J Neurosci"},{"key":"3780_CR75","first-page":"551","volume":"27","author":"C Verghese","year":"1991","unstructured":"Verghese C, Kessel JB, Simpson GM (1991) Pharmacokinetics of neuroleptics. Psychopharmacol Bull 27:551\u2013563","journal-title":"Psychopharmacol Bull"},{"key":"3780_CR76","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1046\/j.1471-4159.1997.69010182.x","volume":"69","author":"M Volonte","year":"1997","unstructured":"Volonte M, Monferini E, Cerutti M, Fodritto F, Borsini F (1997) BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J Neurochem 69:182\u2013190","journal-title":"J Neurochem"},{"key":"3780_CR77","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1126\/science.6136093","volume":"221","author":"FJ White","year":"1983","unstructured":"White FJ, Wang RY (1983) Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221:1054\u20131057","journal-title":"Science"},{"key":"3780_CR78","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejphar.2005.11.003","volume":"528","author":"D Wirtshafter","year":"2005","unstructured":"Wirtshafter D, Osborn CV (2005) The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats. Eur J Pharmacol 528:88\u201394","journal-title":"Eur J Pharmacol"},{"key":"3780_CR79","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.1523\/JNEUROSCI.21-16-06338.2001","volume":"21","author":"Q Wu","year":"2001","unstructured":"Wu Q, Reith ME, Kuhar MJ, Carroll FI, Garris PA (2001) Preferential increases in nucleus accumbens dopamine after systemic cocaine administration are caused by unique characteristics of dopamine neurotransmission. J Neurosci Off J Soc Neurosci 21:6338\u20136347","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"3780_CR80","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0149-7634(99)00065-2","volume":"24","author":"DS Zahm","year":"2000","unstructured":"Zahm DS (2000) An integrative neuroanatomical perspective on some subcortical substrates of adaptive responding with emphasis on the nucleus accumbens. Neurosci Biobehav Rev 24:85\u2013105","journal-title":"Neurosci Biobehav Rev"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-014-3780-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-014-3780-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-014-3780-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T14:27:04Z","timestamp":1746455224000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-014-3780-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,28]]},"references-count":80,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["3780"],"URL":"https:\/\/doi.org\/10.1007\/s00213-014-3780-2","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,28]]}}}